AZD8797 (KAND567) is a selective, orally bioavailable antagonist of human CX3CR1 and CXCR2. It has shown potential in research models to protect against SARS-CoV-2-related neuronal damage and to attenuate migraine-associated nociceptive sensitization and microglial activation in post-seizure rats.